Do IL-5-targeting therapies for asthma have a protective
effect in COVID-19 patients with severe asthma who are already receiving
these therapies?
There is neither evidence for a protective effect of these biologicals
nor a negative effect regarding SARS-CoV-2 infection. Importantly,
maintaining proper asthma control is imperative and so is to follow up
on severe asthmatics during the COVID-19 pandemic, for example via
telemedicine.44